Effects of Recoverben® on Recovery After Exhaustive Exercise

November 1, 2017 updated by: Vital Solutions GmbH

Effects of Recoverben® on Recovery After Exhaustive Exercise in Healthy People - a Randomized, Double-blind, Placebo-controlled Study With Parallel Design

The aim of the study is to investigate a pre and post workout supplementation (15 days) with Recoverben® , a Aloysia citriodora extract on recovery after exhaustive exercise. Effects will be investigated with 400mg Recoverben® and compared to placebo.

Study Overview

Detailed Description

The aim of the study is to investigate a pre and post workout supplementation (15 days) with Recoverben® , a Aloysia citriodora extract on recovery after exhaustive exercise. Effects will be investigated with 400mg Recoverben® and compared to placebo.

Targeted parameter will be determined at the beginning of the study and after supplementation, each. Parameter include maximal strength (MVC), muscle soreness (VAS), pain sensitivity (Algometry) and biomarkers (CK, IL-6, glutathione peroxidase).

Study Type

Interventional

Enrollment (Actual)

40

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Esslingen, Germany, 73728
        • BioTeSys GmbH

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

22 years to 50 years (ADULT)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Subject is able and willing to sign the Informed Consent Form prior to screening evaluations
  • Health volunteers: Subject is in good physical and mental health as established by medical his-tory, physical examination, electrocardiogram, vital signs, results of biochemistry and haematology
  • Men and women
  • Age ≥ 22 and ≤ 50 years
  • BMI: 19-30 kg/m2
  • Physically active 1-3 times per week
  • Nonsmoker
  • Able and willing to follow the study protocol procedures

Exclusion Criteria:

  • Relevant history, presence of any medical disorder or chronic intake of medication/dietary supplements (e.g. polyphenols, anti-inflammatory or anti-oxidative drugs or supplements, antihyper-tensive drugs) potentially interfering with this study at screening.
  • For this study clinically relevant abnormal laboratory, vital signs or physical findings at screening
  • Diabetes or serious cardiovascular diseases
  • Change of dietary habits within the 2 weeks prior to screening (for instance start of a diet high in vegetables and fruits (≥ 5 portions per day))
  • Diet high in vegetables and fruits ≥ 5 portions per day
  • Participants anticipating a change in their lifestyle or physical activity levels during the study.
  • Subjects not willing to abstain from intake of analgesic medication (e.g. Aspirin) 24 hours prior to visit 2 until visit 5.
  • Subjects with history of drug, alcohol or other substances abuse, or other factors limiting their ability to co-operate during the study.
  • Known hypersensitivity to the study preparation or to single ingredients
  • Pregnant subject or subject planning to become pregnant during the study; breast-
  • Known HIV-infection
  • Known acute or chronic hepatitis B and C infection
  • Blood donation within 4 weeks prior to visit 1 or during the study.
  • Subject involved in any clinical or food study within the preceding month

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: PREVENTION
  • Allocation: RANDOMIZED
  • Interventional Model: PARALLEL
  • Masking: QUADRUPLE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
ACTIVE_COMPARATOR: Aloysia citriodora extract
Dietary Supplement: Aloysia citriodora extract
2 capsules with 200mg - daily dosage 400mg
Other Names:
  • Recoverben®
PLACEBO_COMPARATOR: Placebo Formulation
Dietary Supplement: Maltodextrin (no active ingredient)
2 capsules with 200mg - daily dosage 400mg
Other Names:
  • Placebo

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change of muscle soreness (VAS) over time
Time Frame: Chance over time after 10 days of supplementation (pre stress test and 3h, 24h, 48 h, 96h after stress test)
In the current study, pain following eccentric exercise will be assessed by using a 100 mm visual analogue scale after the subjects performing a standardized movement.
Chance over time after 10 days of supplementation (pre stress test and 3h, 24h, 48 h, 96h after stress test)

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Monitoring of related adverse events
Time Frame: During study execution over 15 days
Reporting of adverse effects to evaluate tolerability
During study execution over 15 days
Change of maximal concentric strength/ maximal voluntary contraction (MVC) over time
Time Frame: Chance over time after 10 days of supplementation (pre stress test and 3h, 24h and 48 h after stress test)
Maximal concentric strength of the M. Quadriceps femoris will be assessed by measuring maximal isometric concentric strength using a dynamometer
Chance over time after 10 days of supplementation (pre stress test and 3h, 24h and 48 h after stress test)
Change of pressure pain (Algometry) over time
Time Frame: Chance over time after 10 days of supplementation (pre stress test and 3h, 24h and 48 h after stress test)
The threshold for pressure induced pain will be measured using an algometer.
Chance over time after 10 days of supplementation (pre stress test and 3h, 24h and 48 h after stress test)
Change of retrospective pain (Likert scale) over time
Time Frame: Chance over time after 10 days of supplementation (pre stress test and 24h, 48h, 96h after stress test)
Evaluation of the perceived pain retrospectively by using the Likert scale for muscle soreness
Chance over time after 10 days of supplementation (pre stress test and 24h, 48h, 96h after stress test)
Change of creatine kinase over time
Time Frame: Chance over time after 10 days of supplementation (pre stress test and 3h, 24h and 48 h after stress test)
Chance over time after 10 days of supplementation (pre stress test and 3h, 24h and 48 h after stress test)
Change of of glutathione peroxidase over time
Time Frame: Chance over time after 10 days of supplementation (pre stress test and 24h and 48 h after stress test)
Chance over time after 10 days of supplementation (pre stress test and 24h and 48 h after stress test)
Change of interleukin-6 over time
Time Frame: Chance over time after 10 days of supplementation (pre stress test and 3h, 24h and 48 h after stress test)
Chance over time after 10 days of supplementation (pre stress test and 3h, 24h and 48 h after stress test)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Chair: Claudia Reule, Dr., BioTeSys GmbH

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

October 1, 2016

Primary Completion (ACTUAL)

January 15, 2017

Study Completion (ACTUAL)

March 15, 2017

Study Registration Dates

First Submitted

September 28, 2016

First Submitted That Met QC Criteria

September 30, 2016

First Posted (ESTIMATE)

October 4, 2016

Study Record Updates

Last Update Posted (ACTUAL)

November 6, 2017

Last Update Submitted That Met QC Criteria

November 1, 2017

Last Verified

November 1, 2017

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Healthy Volunteers

Clinical Trials on Aloysia citriodora extract

3
Subscribe